Upgrade to SI Premium - Free Trial

NSRX (NSRX)

3.74 -0.01 (0.27%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (12/2/26)

Latest Headlines

Form 6-K Nasus Pharma Ltd For: Sep 04 September 4, 2026 4:05 PM - SEC Filing Form F-3 Nasus Pharma Ltd September 1, 2026 4:51 PM - SEC Filing Form EFFECT Nasus Pharma Ltd August 21, 2026 6:05 AM - SEC Filing Form 6-K Nasus Pharma Ltd For: Aug 19 August 19, 2026 9:21 AM - SEC Filing Nasus Pharma CFO departs, interim replacement named August 19, 2026 7:00 AM - StreetInsider Nasus Pharma Announces Transition of Chief Financial Officer August 19, 2026 7:00 AM - Globe NewsWire Form POS AM Nasus Pharma Ltd August 19, 2026 6:01 AM - SEC Filing Form 6-K Nasus Pharma Ltd For: Jun 30 August 17, 2026 8:41 AM - SEC Filing Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update August 17, 2026 8:14 AM - Globe NewsWire Form SCHEDULE 13G/A Nasus Pharma Ltd Filed by: BALYASNY ASSET MANAGEMENT L.P. August 14, 2026 6:14 AM - SEC Filing Form 3 Nasus Pharma Ltd For: Jul 27 Filed by: O'Grady Brendan P. July 31, 2026 4:26 PM - SEC Filing Form 4 Nasus Pharma Ltd For: Jul 22 Filed by: Teleman Dan Benjamin July 29, 2026 5:01 PM - SEC Filing Form 6-K Nasus Pharma Ltd For: Jul 28 July 28, 2026 8:35 AM - SEC Filing Nasus Pharma names Brendan O'Grady as new CEO July 28, 2026 7:30 AM - StreetInsider Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth July 28, 2026 7:30 AM - Globe NewsWire Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th June 23, 2026 8:35 AM - Globe NewsWire Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum June 22, 2026 8:00 AM - Globe NewsWire Form 4 Nasus Pharma Ltd For: Jun 17 Filed by: Teleman Dan Benjamin June 22, 2026 7:13 AM - SEC Filing Nasus Pharma (NSRX) Reiterated at Market Outperform by Citizens June 11, 2026 5:15 AM - StreetInsider Form 6-K Nasus Pharma Ltd For: Jun 09 June 9, 2026 4:07 PM - SEC Filing Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron June 9, 2026 8:01 AM - StreetInsider Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)  June 9, 2026 8:00 AM - Globe NewsWire Full Article List